Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: A phase I single-dose escalation trial

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4091-4100

  Gulec, Seza A ^a,g   Cohen, Steven J ^b   Pennington, Kenneth L ^a   Zuckier, Lionel S ^c   Hauke, Ralph J ^d   Horne, Heather ^e   Wegener, William A ^e   Teoh, Nick ^e   Gold, David V ^f   Sharkey, Robert M ^f   Goldenberg, David M ^e,f  

^a Goshen Health System Center for Cancer Care   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e IMMUNOMEDICS INC   (United States)

^f CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^g FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CAPECITABINE; CLIVATUZUMAB TETRAXETAN Y 90; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEMCITABINE; HUMANIZED PAM4 MONOCLONAL ANTIBODY IN 111; IRINOTECAN; PLATINUM; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSTIPATION; CYTOPENIA; DEHYDRATION; DIARRHEA; DISEASE DURATION; DOSIMETRY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GASTROJEJUNOSTOMY; HEPATOJEJUNOSTOMY; HUMAN; IMMUNOGENICITY; INFECTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PAIN; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH OBSTRUCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RADIOMETRY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959273645     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2579     Document Type: Article

References (26)

1. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380-7.
2. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994;57:204-10. (Pubitemid 24144210)
3. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006;24:252-8. (Pubitemid 46622054)
4. Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, et al. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010;19:2786-94.
5. Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res 1995;55:5911s-5s.
6. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of 90yttrium-versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res 2001;7:3186-92. (Pubitemid 32963842)
7. Gold DV, Cardillo T, Vardi Y, Blumenthal R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int J Cancer 1997;71:660-7. (Pubitemid 27239379)
8. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 2002;97:386-92. (Pubitemid 34049033)
9. Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004;109:618-26. (Pubitemid 38339654)
10. Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy (90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S-37S.
11. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003;44:77-84. (Pubitemid 36077716)
12. Augensen FO, Wegener WA, Siegel J, Yeldell D, Sharkey RM, Goldenberg DM. Radiation dosimetry in 90Y radioimmunotherapy (RAIT): development of a method suitable for clinical use with pretherapy 111In imaging. J Nucl Med 2004;45:436P.
13. Augensen FO, Wegener WA, Hamacher KA, Siegel JA, Yeldell D, Sharkey RM, et al. Radiation dosimetry in 90Y radioimmunotherapy (RAIT): phantom testing of a method suitable for clinical use with pretherapy 111In imaging. J Nucl Med 2005;46:340P-1P.
14. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46. (Pubitemid 26094290)
15. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94. (Pubitemid 23115673)
16. Weichselbaum RR, Chen G, Hallahan DE. Biological and physical basis of radiation oncology. In:Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer medicine. 4th ed. Baltimore, MD: Williams & Wilkins; 1997. p.697-726.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
18. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
19. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
20. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of thePRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010;28:15s.
21. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50.
22. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:3709-16.
23. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465-74. (Pubitemid 39586026)
24. Ocean AJ, Guarino MJ, Pennington KL, O'Neil BH, Rocha Lima CS, Bekaii-Saab TS, et al. Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with lowdose gemcitabine (Gem) in advanced pancreatic cancer (APC). J Clin Oncol 2010;28:7S.
25. Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res 1995;55:1105-10.
26. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46:115S-27S.